Medical Device | April 23, 2026
Medtronic launches adaptive deep brain stimulation system for Parkinson’s in India
The system is powered by BrainSense technology, which has received approval from USFDA
The system is powered by BrainSense technology, which has received approval from USFDA
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The new outpatient-focused clinic is designed to address voice, airway and swallowing disorders through advanced diagnostics
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Milestone marks a major leap toward real-time, personalised neuromodulation therapy as India’s Parkinson’s burden rises sharply
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
Subscribe To Our Newsletter & Stay Updated
